EVOQUANT
LightNews LightNews
banner
evoquant.bsky.social
EVOQUANT
@evoquant.bsky.social
19 followers 0 following 2 posts
Evoquant uses AI and bioinformatics to harness microbes, exploring billions of years of evolution to uncover new drug compounds and accelerate treatments for cancer, infectious diseases, and rare conditions.
https://evoquantbio.com/
Posts Replies Media Videos
Reposted by EVOQUANT
chasingmicrobes.bsky.social
I have been struggling with transfers in AWS between EC2 and S3 being way slower than the advertised EC2 bandwidth

Last week I learned about:
aws configure set s3.preferred_transfer_client crt

and now transfers are super duper fast.

The more you know
Otherwise, it resolves to classic. Between versions of the AWS CLI, auto resolution criteria may change. To guarantee use of a specific transfer client, set the preferred_transfer_client configuration variable to the appropriate transfer client listed below. classic - Use the builtin, Python-based transfer client that supports all s3 commands, parameters, and most configuration values. crt - Use the AWS Common Runtime (CRT) transfer client when possible. It is a C-based S3 transfer client that can improve transfer throughput. Currently, the CRT transfer client does not support all of the functionality available in the classic transfer client. The list below details what functionality is currently not supported by the crt transfer client option and the corresponding behavior of the AWS CLI if it is configured to prefer the crt transfer client: S3 to S3 copies - Falls back to using the classic transfer client Region redirects - Transfers fail for requests sent to a region that does not match the region of the targeted S3 bucket. max_concurrent_requests, max_queue_size, multipart_threshold, and max_bandwidth configuration values - Ignores these configuration values.
November 17, 2025 at 3:47 PM
evoquant.bsky.social
🤩 evoquantbio.com 🤩
Screenshot of evoquantbio.com showing the text: EvoQuant LLC AI & Bioinformatics for Next-Generation Natural Product Drug Discovery Contact Us
September 27, 2025 at 2:30 PM
evoquant.bsky.social
🚀 Evoquant has been awarded a $300k Small Business Grant from the National Institutes of Health for our project:

"Leveraging Large-Scale Bioinformatics & AI for Natural Product Drug Discovery and Target Selection"

Hitting the ground running 🏃and excited for the year to come!
Public Health Relevance Statement This research addresses challenges in predicting bioactivity in natural product drug discovery by leveraging advanced AI, computational biology, and multi-omics knowledge graphs. This approach has the potential to accelerate the discovery of new, effective drugs for treating a range of conditions, including cancer, infections, and immune-related diseases, by identifying promising leads that could inform the next generation of therapeutics.
September 15, 2025 at 11:51 PM